FAM83A antisense RNA 1 (FAM83A-AS1) silencing impairs cell proliferation and induces autophagy via MET-AMPKɑ signaling in lung adenocarcinoma

ABSTRACT Studies demonstrate that long non-coding RNAs (lncRNAs) play vital roles in cancer progression. However, the expression pattern and molecular mechanisms of lncRNA FAM83A-AS1 in lung cancer remain largely unclear. Here, we analyzed FAM83A-AS1 expression in lung cancer tissues from three RNA-sequencing (RNA-Seq) datasets and validated these results using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) in an independent set of lung adenocarcinoma. Cell proliferation, migration, invasion, and autophagy were analyzed after knockdown FAM83A-AS1 with siRNAs. The underlying molecular mechanisms of FAM83A-AS1 were performed by Western blot, qRT-PCR, and RNA-seq analysis. We found that FAM83A-AS1 was up-regulated in lung cancer and elevated expression was associated with poor patient survival. These results were confirmed using RT-PCR in an independent set of lung cancer. Functional study indicated that FAM83A-AS1 knockdown reduced cell proliferation, migration, invasion, and colony formation in cancer cells. FAM83A-AS1 silencing induced autophagy and cell cycle arrest at G2. Mechanistically, serval oncogenic proteins such as EGFR, MET, PI3K, and K-RAS were decreased upon FAM83A-AS1 silencing, while phosphor AMPKα and ULK1 were increased. Based on the above results, we believe that FAM83A-AS1 may have potential as a diagnosis/prognosis marker and its oncogenic role and autophagy regulation may be through MET-AMPKα signaling, which could lead to potential targeting for lung cancer therapy. GRAPHICAL ABSTRACT

[1]  Hongyu Huang,et al.  Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression , 2022, Bioengineered.

[2]  C. Zhan,et al.  LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma , 2022, International Journal of Biological Sciences.

[3]  Chengming Ding,et al.  LncRNA FAM83A‐AS1 promotes lung adenocarcinoma progression by enhancing the pre‐mRNA stability of FAM83A , 2021, Thoracic cancer.

[4]  Jing Luo,et al.  FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma , 2021, Oncology letters.

[5]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[6]  F. He,et al.  LncRNA FAM83A-AS1 promotes ESCC progression by regulating miR-214/CDC25B axis , 2021, Journal of Cancer.

[7]  D. Beer,et al.  Silencing of LOC389641 impairs cell proliferation and induces autophagy via EGFR/MET signaling in lung adenocarcinoma , 2020, Aging.

[8]  E. Song,et al.  LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer , 2020, Nature Communications.

[9]  D. Beer,et al.  LINC00857 Interacting with YBX1 to Regulate Apoptosis and Autophagy via MET and Phosphor-AMPKa Signaling , 2020, Molecular therapy. Nucleic acids.

[10]  G-M Huang,et al.  LncRNA FAM83A-AS1 aggravates the malignant development of esophageal cancer by binding to miR-495-3p. , 2020, European review for medical and pharmacological sciences.

[11]  Yang-Hsiang Lin Crosstalk of lncRNA and Cellular Metabolism and Their Regulatory Mechanism in Cancer , 2020, International journal of molecular sciences.

[12]  Z. Zeng,et al.  Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA , 2020, Molecular Cancer.

[13]  D. Beer,et al.  Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer , 2020, Autophagy.

[14]  Jinyu He,et al.  Long noncoding RNA FAM83A-AS1 facilitates hepatocellular carcinoma progression by binding with NOP58 to enhance the mRNA stability of FAM83A , 2019, Bioscience reports.

[15]  Xin Sun,et al.  FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14 , 2019, Cell cycle.

[16]  W. Zhuo,et al.  Emerging roles of lncRNA in cancer and therapeutic opportunities. , 2019, American journal of cancer research.

[17]  Juan Li,et al.  Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer , 2019, Molecular Cancer.

[18]  Tao Wang,et al.  Long noncoding antisense RNA FAM83A‐AS1 promotes lung cancer cell progression by increasing FAM83A , 2019, Journal of cellular biochemistry.

[19]  Yingyu Chen,et al.  AMPK and Autophagy. , 2019, Advances in experimental medicine and biology.

[20]  V. Freitas,et al.  Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression , 2018, International journal of molecular sciences.

[21]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[22]  T. Ochiya,et al.  Emerging roles of long non‐coding RNA in cancer , 2018, Cancer science.

[23]  D. Beer,et al.  Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. , 2018, Cancer research.

[24]  Jie He,et al.  Cancer incidence and mortality in China, 2014. , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[25]  H. Bian,et al.  Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets , 2018, PeerJ.

[26]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[27]  Zhongming Zhao,et al.  Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition , 2017, Nature Communications.

[28]  M. Zhou,et al.  Trend analysis of cancer incidence and mortality in China , 2017, Science China Life Sciences.

[29]  S. Diederichs,et al.  Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. , 2017, Journal of hepatology.

[30]  D. Beer,et al.  Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer , 2017, Scientific Reports.

[31]  Young Hak Kim,et al.  Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer , 2017, Oncotarget.

[32]  Shumei Feng,et al.  Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer , 2017, Scientific Reports.

[33]  Z. Qin,et al.  The role of HGF/c-MET signaling pathway in lymphoma , 2016, Journal of Hematology & Oncology.

[34]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[35]  S. Dhanasekaran,et al.  Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer , 2016, Oncotarget.

[36]  Yi-long Wu,et al.  Targeting the MET pathway for potential treatment of NSCLC , 2015, Expert opinion on therapeutic targets.

[37]  S. Dhanasekaran,et al.  Transcriptome Meta-Analysis of Lung Cancer Reveals Recurrent Aberrations in NRG1 and Hippo Pathway Genes , 2014, Nature Communications.

[38]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[39]  Jeannie T. Lee,et al.  Long Noncoding RNAs: Past, Present, and Future , 2013, Genetics.

[40]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[41]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[42]  P. Ma,et al.  MET signaling: novel targeted inhibition and its clinical development in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Cole Trapnell,et al.  Role of Rodent Secondary Motor Cortex in Value-based Action Selection Nih Public Access Author Manuscript , 2006 .

[44]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[45]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[46]  T. Nakajima,et al.  Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance , 1996, Japanese journal of cancer research : Gann.

[47]  C. Cooper,et al.  Tyrosine kinase receptor indistinguishable from the c-met protein , 1989, Nature.

[48]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[49]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.